FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
13.0 pts (24h)Health & MedicineOne-Off3mo
KalshiCheck availabilityKYC required2% feeVerified resolution dataFairly calibratedCurrent implied probability
Yes 98%+13.0pt
Market quality
47 / 100
Low quality24h Volume
$558
Liquidity
$1.5K
Low liquidityBid / Ask
91.0% / 99.0%
Spread
8.0 pt
Wide spreadMarket data
Updated 10 minutes ago
Jun 17, 26, 9:30 PM UTCJan 1, 27, 4:59 AM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRules
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Settles via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in.
- It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma.
- In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.
Open markets
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Total Vol
- $18.1M
- 24h Vol
- $22.1K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Total Vol
- $1.9M
- 24h Vol
- $6K
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 more outcomes
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Total Vol
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Total Vol
- $1.1M
- 24h Vol
- $1.8K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000-1.0pt96%
- Above 6000+1.0pt60%
+2 more outcomes
- Total Vol
- $1M
- 24h Vol
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
Frequently asked questions
- What are the current odds for FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- Kalshi prices Yes at 98% as of September 8, 2026.
- When does FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) resolve?
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) is scheduled to resolve on January 1, 2027.
- How is FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) settled?
- Kalshi settles this market as follows: If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.